Madrigal Pharmaceuticals beat Q1 sales estimates with Rezdiffra, and catalysts like EU approval and pipeline plans add upside ...

Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has demonstrated sustained efficacy in a late-stage trial of patients with ...

Duffy is the second member of Trump’s cabinet who sold securities shortly before the president’s tariff announcements sent ...

Detailed price information for Arrowhead Pharma (ARWR-Q) from The Globe and Mail including charting and trades.

Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for ...

DelveInsight's analysis forecasts liver fibrosis market growth due to the introduction of emerging therapies, expecting an increase in market size during the study period (2020–2034). This anticipated ...

In trading on Wednesday, shares of Madrigal Pharmaceuticals Inc (Symbol: MDGL) crossed below their 200 day moving average of $292.11, changing hands as low as $287.01 per share. Madrigal ...

The most significant addition was Honeywell International Inc (NASDAQ:HON), with 200,000 shares, accounting for 2.42% of the ...

Shares of Akero Therapeutics (NASDAQ:AKRO) climbed on Tuesday after StreetInsider reported that the San Francisco, California ...

As Madrigal Pharmaceuticals prepared for FDA approval of the first treatment... We’re long-term subscribers to WARC and it’s a tool we use extensively. We use it to source case studies and best ...